Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis, the most common adult-onset motor neuron disease, leads to death within 3 to 5 years after onset. Beyond progressive motor impairment, patients with amyotrophic lateral sclerosis suffer from major defects in energy metabolism, such as weight loss, which are well correlated with survival. Indeed, nutritional intervention targeting weight loss might improve survival of patients. However, the neural mechanisms underlying metabolic impairment in patients with amyotrophic lateral sclerosis remain elusive, in particular due to the lack of longitudinal studies. Here we took advantage of samples collected during the clinical trial of pioglitazone (GERP-ALS), and characterized longitudinally energy metabolism of patients with amyotrophic lateral sclerosis in response to pioglitazone, a drug with well-characterized metabolic effects. As expected, pioglitazone decreased glycaemia, decreased liver enzymes and increased circulating adiponectin in patients with amyotrophic lateral sclerosis, showing its efficacy in the periphery. However, pioglitazone did not increase body weight of patients with amyotrophic lateral sclerosis independently of bulbar involvement. As pioglitazone increases body weight through a direct inhibition of the hypothalamic melanocortin system, we studied hypothalamic neurons producing proopiomelanocortin (POMC) and the endogenous melanocortin inhibitor agouti-related peptide (AGRP), in mice expressing amyotrophic lateral sclerosis-linked mutant SOD1(G86R). We observed lower Pomc but higher Agrp mRNA levels in the hypothalamus of presymptomatic SOD1(G86R) mice. Consistently, numbers of POMC-positive neurons were decreased, whereas AGRP fibre density was elevated in the hypothalamic arcuate nucleus of SOD1(G86R) mice. Consistent with a defect in the hypothalamic melanocortin system, food intake after short term fasting was increased in SOD1(G86R) mice. Importantly, these findings were replicated in two other amyotrophic lateral sclerosis mouse models based on TDP-43 (Tardbp) and FUS mutations. Finally, we demonstrate that the melanocortin defect is primarily caused by serotonin loss in mutant SOD1(G86R) mice. Altogether, the current study combined clinical evidence and experimental studies in rodents to provide a mechanistic explanation for abnormalities in food intake and weight control observed in patients with amyotrophic lateral sclerosis. Importantly, these results also show that amyotrophic lateral sclerosis progression impairs responsiveness to classical drugs leading to weight gain. This has important implications for pharmacological management of weight loss in amyotrophic lateral sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis
Brettschneider, J., Del Tredici, K., Toledo, J. B., Robinson, J. L., Irwin, D. J., Grossman, M., Suh, E., Van Deerlin, V. M., Wood, E. M., Baek, Y., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23937 · Cited by 1,065
Self-citationExome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways
Cirulli, E. T., Lasseigne, B. N., Petrovski, S., Sapp, P. C., Dion, P. A., Leblond, C. S., Couthouis, J., Lu, Y.-F., Wang, Q., Krueger, B. J., et al. (2015) · Science · doi:10.1126/science.aaa3650 · Cited by 966
Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia
Freischmidt, A., Wieland, T., Richter, B., Ruf, W., Schaeffer, V., Müller, K., Marroquin, N., Nordin, F., Hübers, A., Weydt, P., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4000 · Cited by 786
Self-citationPioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Neurobiology of food intake in health and disease
Morton, G. J., Meek, T. H., & Schwartz, M. W. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3745 · Cited by 748
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration
Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M., & Baloh, R. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908767106 · Cited by 706
Cited by
Energy metabolism in ALS: an underappreciated opportunity?
Vandoorne, T., De Bock, K., & Van Den Bosch, L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1835-x · Cited by 262
Self-citationVercruysse, P., Vieau, D., Blum, D., Petersén, Å., & Dupuis, L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00002 · Cited by 172
“This could be due to intrinsic defects in the hypothalamic MCH neurons as we observed multiple defects in POMC and AgRP neurons in these mice (Vercruysse et al., 2016).”
BackgroundSelf-citationHypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis
Gorges, M., Vercruysse, P., Müller, H.-P., Huppertz, H.-J., Rosenbohm, A., Nagel, G., Weydt, P., Petersén, Å., Ludolph, A. C., Kassubek, J., et al. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-315795 · Cited by 171
Self-citationEffect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis
Ludolph, A. C., Dorst, J., Dreyhaupt, J., Weishaupt, J. H., Kassubek, J., Weiland, U., Meyer, T., Petri, S., Hermann, A., Emmer, A., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25661 · Cited by 169
Self-citationPeter, R. S., Rosenbohm, A., Dupuis, L., Brehme, T., Kassubek, J., Rothenbacher, D., Nagel, G., & Ludolph, A. C. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0318-z · Cited by 113
Self-citationPhysiological changes in neurodegeneration—mechanistic insights and clinical utility
Ahmed, R. M., Ke, Y. D., Vucic, S., Ittner, L. M., Seeley, W., Hodges, J. R., Piguet, O., Halliday, G., & Kiernan, M. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.23 · Cited by 91
Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis
El Oussini, H., Scekic‐Zahirovic, J., Vercruysse, P., Marques, C., Dirrig‐Grosch, S., Dieterlé, S., Picchiarelli, G., Sinniger, J., Rouaux, C., & Dupuis, L. (2017) · Annals of Neurology · doi:10.1002/ana.25030 · Cited by 47
Self-citationMichels, S., Kurz, D., Rosenbohm, A., Peter, R. S., Just, S., Bäzner, H., Börtlein, A., Dettmers, C., Gold, H.-J., Kohler, A., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11630-4 · Cited by 35
“ALS patients exhibit an increased energy expenditure at rest [1, 10, 12, 13], which might be related to hypothalamic [14, 15] and/or mitochondrial dysfunction [16, 17].”
BackgroundSelf-citationAhmed, R. M., Tse, N. Y., Chen, Y., Henning, E., Hodges, J. R., Kiernan, M. C., Irish, M., Farooqi, I. S., & Piguet, O. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51369 · Cited by 12
Metadata
- Authors
- Vercruysse, P., Sinniger, J., El Oussini, H., Scekic-Zahirovic, J., Dieterlé, S., Dengler, R., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., Dreyhaupt, J., Grehl, T., Hermann, A., Grosskreutz, J., Witting, A., Van Den Bosch, L., Spreux-Varoquaux, O., the GERP ALS Study Group, Ludolph, A. C., & Dupuis, L.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-16
- Volume
- 139
- Issue
- 4
- Pages
- 1106-1122
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2309136250
- Cited by
- 104
- References
- 16
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.